About MimiVax
We got tired of curing glioblastoma in test tubes.
MimiVax was founded by neuro-oncology clinicians who saw patients with little or no hope every day, and decided the lab-to-clinic gap was the problem worth closing.
Our story
Bench to bedside, on purpose.
We were part of a neuro-oncology clinic. We saw patients every day with little or no hope, and we had to do something. Our first grant was a research scholarship from the American Cancer Society — the start of a straight line from small early studies to the confirmatory trial underway today.
We follow the data. That's what got us here, and it's what will take SurVaxM into the indications ahead. We're adding new, distinct options where there were previously none.
Our mission
To disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates.
At a glance
Fifteen years in, still in the same fight.
Privately held
Headquartered at Elm & Carlton Streets, Buffalo, NY, alongside the clinical environment where SurVaxM began.
Founder-led science
Co-invented by our CEO and CMO, who continue to lead the science today — see the full leadership page.
Two federal designations
SurVaxM already holds FDA Orphan Drug and Fast Track designations.
Where the evidence stands
See every program, phase by phase.
The Pipeline page is the fullest picture of where SurVaxM and the earlier-stage programs stand today.